The clinical study of chest radiotherapy and optimal timing of intervention in oligometastatic stage Ⅳ NSCLC
10.3760/cma.j.issn.1004-4221.2018.11.005
- VernacularTitle:Ⅳ期寡转移NSCLC放疗及最佳介入时机研究
- Author:
Ruining LI
1
;
Xiaomin LI
;
Qi LI
;
Yaqiong REN
;
Yajuan WU
;
Yuejun REN
Author Information
1. 山西医科大学附属肿瘤医院放疗中心
- Keywords:
Lung neoplasm/radiotherapy;
Oligometastasis;
Intervention timing;
Prognosis
- From:
Chinese Journal of Radiation Oncology
2018;27(11):975-979
- CountryChina
- Language:Chinese
-
Abstract:
Objective To clarify the significance of chest radiotherapy in the treatment of oligometastatic stage Ⅳ non-small cell lung cancer ( NSCLC ) and to explore the optimal time of interventional therapy during chest radiotherapy. Methods A total of 192 patients with oligometastatic stage Ⅳ NSCLC admitted to Shanxi Provincial Cancer Hospital from 2008 to 2014 were randomly and evenly divided into the chemotherapy alone, radiotherapy+ early intervention, radiotherapy+ middle intervention and radiotherapy+ late intervention groups. Survival analysis was performed with Kanplan-Meier method. Results The median survival of 192 patients with oligometastatic stage Ⅳ NSCLC was 14. 50 months, and the 1-,2-and 3-year survival rates were 57. 4％,24. 0％ and 10. 7％, respectively. The median survivalin the chemotherapy alone, radiotherapy+ early intervention, radiotherapy+ middle intervention and radiotherapy+late intervention groups was 10,21,18 and 13 months, respectively. The 1-year survival rates were 34％, 73％,71％ and 51％,10％,40％,32％ and 13％ for the 2-year survival rates, and 0％,24％,16％ and 3％for the 3-year survival rates ( P=0. 000) . The median survival of patients with radiotherapy dose ≥ 60 Gy and< 60 Gy was 21 and 13 months, 76％ and 53％ for the 1-year survival rates, 34％ and 21％ for the 2-year survival rates, and 17％ and 10％ for the 3-year survival rates ( P=0. 002 ) . Conclusion Early interventional therapy and high-dose radiotherapy can improve the local control rate and prolong the survival time of patients with oligometastatic stage Ⅳ NSCLC.
